[go: up one dir, main page]

CA3277013A1 - Molécules de fusion d'anticorps bispécifiques et leurs procédés d'utilisation - Google Patents

Molécules de fusion d'anticorps bispécifiques et leurs procédés d'utilisation

Info

Publication number
CA3277013A1
CA3277013A1 CA3277013A CA3277013A CA3277013A1 CA 3277013 A1 CA3277013 A1 CA 3277013A1 CA 3277013 A CA3277013 A CA 3277013A CA 3277013 A CA3277013 A CA 3277013A CA 3277013 A1 CA3277013 A1 CA 3277013A1
Authority
CA
Canada
Prior art keywords
methods
bispecific antibody
antibody fusion
fusion molecules
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3277013A
Other languages
English (en)
Inventor
Jeremy S Myers
Eric M Tam
Mohosin Sarkar
Guixian Jin
Xingyue An
Stella Aviaty Martomo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evolveimmune Therapeutics Inc
Original Assignee
Evolveimmune Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evolveimmune Therapeutics Inc filed Critical Evolveimmune Therapeutics Inc
Publication of CA3277013A1 publication Critical patent/CA3277013A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
CA3277013A 2022-12-14 2023-12-14 Molécules de fusion d'anticorps bispécifiques et leurs procédés d'utilisation Pending CA3277013A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263432665P 2022-12-14 2022-12-14
PCT/US2023/084129 WO2024130032A1 (fr) 2022-12-14 2023-12-14 Molécules de fusion d'anticorps bispécifiques et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
CA3277013A1 true CA3277013A1 (fr) 2024-06-20

Family

ID=89983446

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3277013A Pending CA3277013A1 (fr) 2022-12-14 2023-12-14 Molécules de fusion d'anticorps bispécifiques et leurs procédés d'utilisation

Country Status (5)

Country Link
EP (1) EP4634228A1 (fr)
AU (1) AU2023398887A1 (fr)
CA (1) CA3277013A1 (fr)
IL (1) IL321437A (fr)
WO (1) WO2024130032A1 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2956471C (fr) * 2014-07-31 2024-09-10 Amgen Res Munich Gmbh Constructions optimisees d'anticorps monocatenaires, bispecifiques, specifiques d'especes croisees
WO2016105450A2 (fr) * 2014-12-22 2016-06-30 Xencor, Inc. Anticorps trispécifiques
CN114478792A (zh) * 2015-01-08 2022-05-13 根马布股份公司 针对cd3和cd20的双特异性抗体
IL319047A (en) * 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
EP3356420B1 (fr) * 2015-10-02 2023-11-01 F. Hoffmann-La Roche AG Anticorps multispécifiques
IL315714A (en) * 2022-03-18 2024-11-01 Evolveimmune Therapeutics Inc Bispecific antibody fusion molecules and methods of using them

Also Published As

Publication number Publication date
AU2023398887A1 (en) 2025-06-26
EP4634228A1 (fr) 2025-10-22
WO2024130032A1 (fr) 2024-06-20
IL321437A (en) 2025-08-01

Similar Documents

Publication Publication Date Title
CA3254549A1 (fr) Molécules de fusion d'anticorps bispécifiques et leurs procédés d'utilisation
CA3258000A1 (fr) Molécules de liaison fcrn/antigène et procédés d'utilisation
IL316368A (en) Anti-TL1A antibodies and methods of using them
IL305827A (en) Bispecific antibodies targeting CD47 and PD-L1 and methods of using them
IL316065A (en) Anti-CD28 antibodies and methods of using them
IL305828A (en) Bispecific antibodies targeting CD47 and PD-L1 and methods of using them
CA3266793A1 (fr) Anticorps anti-b7h3 et méthodes d'utilisation
IL317690A (en) Anti-GPNMB antibodies and methods of using them
IL318694A (en) Antibodies against CCR8 and methods of using them
IL315845A (en) Anti-dectin-1 antibodies and methods of using them
IL323285A (en) Anti-phosphocholine antibodies and methods of using them
CA3277013A1 (fr) Molécules de fusion d'anticorps bispécifiques et leurs procédés d'utilisation
HK40120830A (zh) 双特异性抗体融合分子及其使用方法
HK40120973A (en) Bispecific antibody fusion molecules and methods of use thereof
CA3266931A1 (fr) Anticorps anti-napi2b et procédés d'utilisation
IL319674A (en) Human anti-IL-1R3 antibody and methods of use
CA3261520A1 (fr) Anticorps, leurs procédés de fabrication et leurs méthodes d'utilisation
HK40101180A (zh) 双特异性抗mertk和抗pdl1抗体及其使用方法
HK40108333A (zh) 双特异性抗体及使用方法
HK40110029A (en) Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
HK40112454A (zh) Lilrb2特异性单克隆抗体及其使用方法
HK40112298A (zh) Osmr特异性单克隆抗体及其使用方法
CA3260904A1 (fr) Constructions d'anticorps multivalents et bispécifiques et leurs procédés d'utilisation
IL311003A (en) Anti-2HER antibodies and methods of using them
IL323599A (en) Anti-IL-25 antibodies and methods of using them